Introduction to the Glaucoma and Cancer Association

The complex glaucoma and cancer association is becoming increasingly significant as global survival rates for various malignancies improve. Recent clinical evidence suggests that the presence of either intraocular or non-ocular cancers can substantially influence the risk and progression of glaucoma. Consequently, understanding these interactions is vital for clinicians to prevent irreversible vision loss in oncological patients. This relationship encompasses both the direct pathological effects of tumors and the secondary consequences of life-saving cancer treatments.

Prevalence and Clinical Implications

Extensive research indicates a notable increase in glaucoma prevalence among patients diagnosed with both intraocular and non-ocular cancers. Specifically, studies have found that when intraocular cancers co-occur with glaucoma, there is an elevated risk of regional invasion, metastases, and high-risk histopathological features. This suggests that glaucoma may serve as an early clinical marker for potential complications or a poorer prognosis in ocular malignancies. Moreover, the systematic consolidation of these relationships allows for better risk stratification during the diagnostic process.

The Role of Cancer Therapies in Ocular Health

Cancer treatments play a dual role in the glaucoma and cancer association. For instance, the use of corticosteroids is a common component in many chemotherapy regimens, yet these agents are frequently linked to significant elevations in intraocular pressure (IOP). If left unmanaged, this steroid-induced hypertension can lead to secondary glaucoma. Conversely, certain treatments like androgen deprivation therapy (ADT) for prostate cancer have shown a surprising correlation with a lowered risk of glaucoma development. These findings highlight the need for a personalized approach to eye care depending on the specific oncological intervention used.

Monitoring the Glaucoma and Cancer Association

Effective management requires a proactive strategy to monitor patients following a cancer diagnosis or during active therapy. Clinicians should consider baseline eye examinations for patients starting high-dose steroid treatments. Furthermore, multidisciplinary collaboration between oncologists and ophthalmologists is essential to manage secondary glaucoma effectively. By identifying risk factors early, healthcare providers can implement strategies that preserve vision without compromising the efficacy of the primary cancer treatment.

Frequently Asked Questions

How does cancer treatment affect my risk of developing glaucoma?

Certain treatments, particularly high-dose corticosteroids used in chemotherapy, can increase intraocular pressure. This elevation can damage the optic nerve, potentially leading to secondary glaucoma if not monitored closely.

Can any cancer therapies actually reduce glaucoma risk?

Yes, some studies indicate that androgen deprivation therapy (ADT) used for prostate cancer is associated with a decreased risk of developing certain types of glaucoma, possibly due to the role of hormones in the disease's pathogenesis.

What should cancer patients do to protect their vision?

Patients should undergo regular eye screenings, especially if their treatment includes steroids. Early detection of rising intraocular pressure allows for prompt intervention and prevents permanent vision loss.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Yim TSY et al. Cancer and glaucoma: A systematic review. Eur J Ophthalmol. 2026 Jun 02. doi: 10.1177/11206721261445522. PMID: 42228376.

2. Lin X, Li S. From tumor microenvironment to ocular hypertension: unraveling the pathogenesis and therapeutic strategies of cancer-related glaucoma. Front Med. 2025;12:1628325.

3. Ahn HK, et al. Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study. Prostate Int. 2021;9(4):197-202.